•Knockdown of endogenous VE-cadherin causes vascular defects without heart failure. 5 6
Introduction 1
Blood vessel networks are distributed widely in the vertebrate body, and they 2 deliver essential substances including oxygen, nutrients, and hormones to tissues and 3 organs (Adams and Alitalo, 2007; Potente et al., 2011) . The vascular system also plays 4 important roles in a variety of functional events such as homeostasis, tissue 5 morphogenesis, regeneration, and cancer metastasis (Carmeliet, 2005; Makita et al., 6 2008; Saito et al., 2012) . During blood vessel formation in embryogenesis, endothelial 7 precursor cells called angioblasts emerge in mesenchymal populations, and 8 subsequently differentiate into endothelial cells to form nascent blood vessels by the 9 process of vasculogenesis (Herbert and Stainier, 2011) . Following vasculogenesis, 10 blood vessels undergo angiogenesis, during which time they change their structures by 11 extending, sprouting, pruning, and remodeling (Adams and Alitalo, 2007; Herbert and 12 Stainier, 2011) . Finally, mature vasculatures become associated with type-specific 13 perivascular cells (Jain, 2003) to complete arterial-venous differentiation. 14 An increasing body of experimental evidence has advanced our understanding 15 of the molecular and cellular mechanisms by which blood vessel formation is regulated. 16
The major approaches used for the analyses have been the endothelial-specific loss-or 17 gain-of-function of genes, for which transgenic animals in mice and zebrafish serve as 18 powerful experimental models (De Val and Black, 2009; Hogan and Schulte-Merker, 19 2017; Stahl et al., 2010) . In these experiments, pan-endothelial drivers, such as Tie1 or 20 Tie2, are often used, and this leads to a transgenesis of the entire cardiovasculature 21 system, including both the heart and vessels (Korhonen et al., 1995; Schlaeger et al., 22 1997) . If heart development is affected by the transgene (for example by interfering 23 with ALK5 or Smad4 expression), then blood flow is frequently undermined; and this 24 loss of mechanical flow can indirectly cause the malformation of peripheral vasculature 25 (De Val and Black, 2009; Lan et al., 2007; Pardanaud et al., 1996; Sridurongrit et al., 26 2008) . This makes it difficult to distinguish between the direct and indirect effects of 27 transgenesis in peripheral vasculatures. 28
Recent reports have shown that the vasculature contains numerous subtypes 29 of blood vessels. There is not only the artero-venus specification, but also the 30 region-specific diversity of shapes and functions of vessel branches, which are being 31 increasingly appreciated (Augustin and Koh, 2017; Pardanaud et al., 1996; Sato et al., 32 2008) . However, how these diverse types of peripheral vasculature are established 33
5'-GCTGGAACCACCATCTAAA-3'; 23
Cdh5-siRNA#2 (at positions 1052-1070 of ORF), 24
5'-CAACAATTACCATTGAAGT-3'; 25
Cdh5-siRNA#3 (at positions 1470-1488 of ORF), 26
5'-GGTAATCATCAGGATTTCA-3'; 27
Luc-siRNA (negative control interfering with Luciferase expression), 28 5'-GGATCCTATCCGAAGGCAA-3'. 29
All sense and anti-sense RNA oligos were synthesized by Eurofins Genomics. 30
Annealing of sense and anti-sense RNA oligos was prepared according to the 31 manufacturer's instruction. Rhodamine labeling of siRNA (Cdh5-siRNA#1) were made 32 using Label IT siRNA Tracker Kit (TAKARA).
1 mRNAs 2
Luciferase and Cdh5mut capped mRNAs were prepared from pBS-Luciferase 3 and pBS-Cdh5mut, respectively, using T7 mScript Standard mRNA Production System 4 (CellScript). 5 6
Cell culture 7
Chicken fibroblast-derived DF1 cells were maintained with Dulbecco's 8
Modified Eagle Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum 9 (FBS) at 38.5°C, 5% CO 2 . For evaluation of Cdh5-siRNA efficacy, pCMV-Cdh5GFP 10
(1,800 ng) and pCAGGS-mCherry (1,000 ng) were co-transfected into DF1 cells along 11 with 30 pmol of each siRNA using Lipofectamine 2000 (Invitrogen). Twenty-four hours 12 after transfection, DF1 cells were fixed overnight in phosphate buffered saline (PBS) 13 containing 4% paraformaldehyde (PFA) at 4°C. Fluorescent images were obtained 14 using AZ-C1 macro-confocal microscope system (Nikon). For cell counting analyses, 15 images were processed using ImageJ (NIH). 16
17

Visualization of blood vessel 18
In vivo visualization of blood vessels was performed by infusion with 19 fluorescent ink as previously described (Takase et al., 2013) . Chicken embryos were 20 infused with 0.5-1 µl highlighter ink (PILOT spotliter; 1:10 dilution in PBS) through the 21 heart using a micropipette pulled from a glass capillary (Narishige, GD-1) with a 22 vertical micropipette puller (Narishige, PC-10). Manipulated embryos were incubated at 23 38.5°C for an additional period of 5 min before harvest. Fluorescent images were 24 obtained using the Leica MZ10 F microscope (Leica) with the DS-Ri1 camera (Nikon). 25
26
In vivo transfection into embryonic vasculature 27
For plasmid DNA transfection, Lipofectamine 2000 (Invitrogen), 28
Lipofectamine 3000 (Invitrogen), ViaFect (Promega), FuGENE HD (Promega) and 29 SuperFect (QIAGEN) were used. Each transfection reagent was diluted with Opti-MEM 30 at 0, 25, 50, 75 or 100% (v/v) , and plasmid DNA solution in Opti-MEM in was 31 separately prepared at 600 ng/µl. Subsequently, the diluted transfection reagent and 32 DNA solution were mixed at a final concentration of 0, 12.5, 25, 37.5 or 50% (v/v) and 33 300 ng/µl, respectively, and incubated at room temperature for 5 min to allow the lipid-1 DNA complex to form. 2 Using a glass micropipette, 0.8 µl of the lipid-DNA complex solution was 3 injected into the heart or the right dorsal aorta (R-DA) at the appropriate embryonic 4 stages. For siRNA transfection, Lipofectamine 2000, siRNA and BLOCK-iT Alexa 5
Fluor Red Fluorescent Control (Invitrogen) were diluted with Opti-MEM at a final 6 concentration of 12.5% (v/v), 5 µM and 2.5 µM, respectively. For siRNA and mRNA 7 transfection, Lipofectamine 2000, rhodamine-labeled Cdh5-siRNA#1 and Luciferase or 8
Cdh5mut mRNA were diluted with Opti-MEM at a final concentration of 12.5% (v/v), 4 9 µM and 360 ng/µl (Luciferase mRNA) or 600 ng/µl (Cdh5mut mRNA), respectively. 10 11 RNA probe and whole-mount in situ hybridization 12 cDNA fragment of chicken Cdh5 was as described (Sato et al., 2008) . 13
Digoxigenin-labeled RNA probe was prepared according to the manufacturer's 14 instruction (Roche). Whole-mount in situ hybridization was performed as previously 15 described (Tonegawa et al., 1997) . 16
17
Frozen sections 18
Chicken embryos were fixed overnight in PBS containing 4% PFA at 4°C. 12.5%, 25%, 37.5%, and 50%, along with 300 ng/µl of pCAGGS-GFP (Fig. 1A) . After 9 17 hours, relatively high levels of GFP signals were observed in the heart and nearby 10 vessels in embryos that received the lipid concentration of 12.5% or 25% (Fig. 1C , n = 11 25; Fig. 1D , n = 40, Table 1 ), whereas a cocktail at concentrations of 37.5% or 50% 12 resulted in barely detectable/no GFP expression or embryonic death (Fig. 1E , F, n = 10 13 each, Table 1 ). Expression levels of GFP were categorized into three classes: no 14 expression (-), moderate (+), and high (++). The highest GFP level with the lowest 15 frequency of embryonic death was achieved with the concentrations of 12.5% or 25% of 16
Lipofectamine 2000 (Table 1 ). 17
We also tested other commercially available reagents for transfection, 18
Lipofectamine 3000 (Invitrogen), ViaFect (Promega), FuGENE HD (Promega), and 19 SuperFect (Qiagen) at the concentration of 25%. Among these, only Lipofectamine 20 3000 yielded GFP signals comparable to those by Lipofectamine 2000 (Table 1) . For 21 further studies, we used Lipofectamine 2000 at 12.5%, since it is less expensive than 22
Lipofectamine 3000. 23
To further scrutinize transfected sites in embryos, we visualized blood vessels 24 of cocktail-injected embryos by ink perfusion prior to harvest 17 hours after transfection 25 (Fig. 1G) (Takase et al., 2013, see also Materials and Methods) . In addition to the heart, 26 GFP signals were widely distributed in blood vessels including intersegmental vessels 27 (ISVs) and yolk sac vasculature (YS) ( We examined whether GFP-transfected sites in the vasculature would differ if 2 the developmental stage and site of cocktail injection were changed. When the 3 lipid-DNA cocktail is injected into a beating heart, the cocktail solution must be 4 delivered by blood flow. In contrast, if injected into an early-formed heart before the 5 circulation starts, the cocktail would spread only locally. Likewise, the delivery pattern 6 of the cocktail must be different if injected into one of paired dorsal aortae. In this way, 7
we compared GFP-transfected areas in vasculature by testing three different 8 developmental stages, 13 ss, 16 ss and 19 ss, and two different sites of injection, the 9 heart and right dorsal aorta (R-DA) (Fig. 2) . Ink was perfused prior to harvest to 10 confirm that the transfected cells were confined to endothelial cells. 11
When injected into the R-DA at the pre-circulation stage (13 ss; no blood 12 flow), an GFP-positive area was within a limited range in the anterior YS of the right 13 side of embryo (R-YS) ( Fig. 2A, H) . In contrast, when injected into the R-DA after the 14 circulation started (16 ss), the GFP-positive area was expanded, and the right vitelline 15 artery (R-VA) was highly labeled (Fig. 2B, I ). When injected into the heart at the same 16 stage (16 ss), the transfected area was seen in both sides of embryo including YSs and 17 VAs (Fig. 2C, F) . 18 VAs, when the cocktail was injected into different stages and different sites; three 21 different embryonic stages of 13 ss (pre-circulation), 16 ss (onset of circulation), and 19 22 ss (circulation established), and two different injection sites, the heart and R-DA, were 23
tested. 24
When injected into the heart of pre-circulation (13 ss), the cocktail remained 25 in limited areas of YSs of both sides of embryos (Fig. 2E) . In contrast, when injected 26 into the heart after the circulation started (16 ss), the cocktail spread widely, and GFP 27 expression was preferentially observed in VAs, in which blood flow was predominant 28 compared to their neighboring vascular plexus (capillaries) (Fig. 2F ). After the 29 establishment of blood circulation, the cocktail injected into the heart spread over the 30 entire vasculature (Fig. 2G , GFP-positive cells in DA, YS, VA are shown). When 31 injected into the right DA, the right half of vasculature exhibited sequential changes in 32 GFP distribution which was similar to those in the case of the heart injection ( Fig. H-J) . 33
Together, site-specific transfection in early chicken vasculature is enabled by adjusting 1 both developmental stages (pre-circulation vs post-circulation) and injection sites of a 2 lipid-DNA cocktail. 3 4 siRNA-mediated Cdh5 knockdown: In vitro assay for evaluation of efficiency 5
To test if the aforementioned method could readily accomplish 6 siRNA-mediated gene knockdown in chicken embryonic vasculature, we used the 7 VE-Cadherin gene (also called cadherin 5 (Cdh5), which is implicated to be important 8 for the assembly of nascent blood vessels in mice (Crosby et al., 2005) . We prepared 9 three siRNAs against the Cdh5 ORF (Cdh5-siRNA#1, #2, #3) (Fig. 3A) . 10
To evaluate the knockdown efficiency by these Cdh5-siRNAs, we performed 11 in vitro assay using chicken fibroblast-derived DF1 cells. The cells were co-transfected 12 with expression vectors of GFP-tagged Cdh5 (Cdh5GFP) and mCherry, the latter being 13 used as an internal control of transfection efficiency, along with each of three 14 Cdh5-siRNAs (Fig. 3B) . Luciferase-siRNA (Luc-siRNA) was used as a negative control. 15 DF1 cells co-transfected with Cdh5GFP, mCherry, and Luc-siRNA displayed both GFP 16 and mCherry signals (Fig. 3C) . In contrast, intensity of GFP signals was reduced when 17 co-transfected with Cdh5-siRNA: a relative ratio of the number of Cdh5GFP + cells to 18 that of mCherry + cells (normalized by the index of Luc-siRNA control) was 0.03 ± 0.02 19 for Cdh5-siRNA#1, 0.55 ± 0.11 for Cdh5-siRNA#2, and 0.19 ± 0.09 for Cdh5-siRNA#3 20 (Fig. 3C, D, n=4 for each). These results indicate that Cdh5-siRNAs prepared in this 21 study could inhibit expression of exogenously introduced Cdh5GFP in culture cells, 22 with Cdh5-siRNA#1 exerting the highest efficiency. 23 24
Site-specific gene knockdown in developing vasculature 25
We next asked whether our flow-mediated gene transfer method was 26 applicable for knocking down endogenous Cdh5, which would also be expected to 27 cause vascular defects. The three Cdh5-siRNAs were separately injected into the right 28 dorsal aorta (R-DA) of 16 ss (HH12) embryos as a 0.8 µl lipid cocktail (12.5% of 29
Lipofectamine 2000, 5 µM of each siRNA, and 2.5 µM of Alexa Fluor Red Fluorescent 30
Control, a fluorescent tracer of siRNA transfection) (Fig. 4A) . When the embryos 31 developed to HH16 (20 hrs post injection), vascular formation was assessed by yellow 32 ink infusion. siRNA-transfected sites were confirmed by co-injected Alexa Fluor Red 1
Fluorescent signals. 2
We found that the formation of R-YS and R-VA was markedly affected, as 3 revealed by both ink perfusion and in situ hybridization with Cdh5 mRNA (Fig. 4C , n = 4 29/32), whereas effects on the vasculature in the left side (L-YS and L-VA) were 5 unrecognizable. Consistent with differential knockdown efficiencies among the three 6 Cdh5-siRNAs (Fig. 3) , embryos injected with Cdh5-siRNA#1 displayed most 7 pronounced defects in vasculature, with siRNA#2 and siRNA#3 showing little and 8 moderate activities, respectively ( Fig. 4C-E ; #1: n=32, #2 and #3: n=17). Vasculatures 9 injected with Luc-siRNA-containing cocktail were indistinguishable from those of 10 untreated embryos (Fig. 4B , n = 15/16). 11
Together, these studies provide proof-of-concept that the blood flow-mediated 12 transfection in vivo with Lipofectamine 2000 can be used for siRNA-knockdown. 13
Importantly, this method allows a site-specific knockdown in vasculature, which has 14 been difficult by conventional genetics such as using Tie2-Cre/flox mice. 15
When the Cdh5-siRNA#1 cocktail was injected into a beating heart, the entire 16 vasculature, including the heart, was severely affected, resulting in malformed embryos 17 (n=18 for Luc-siRNA; n=16 for Cdh5-siRNA#1; Fig. 5 ). Such embryo-wide 18 malformation is reminiscent of phenotypes reported for Cdh5-knockout mice, which die 19 at mid-gestation as a result of severe cardiovascular anomalies, including both vascular 20 and cardiac defects (Carmeliet et al., 1999; Gory-Faure et al., 1999) 
making it difficult 21
to distinguish between direct and indirect effects by the gene knockdown. Thus, the 22 flow-mediated site-specific knockdown described in the current study offers significant 23
merits. 24 25
Rescue of Cdh5 siRNA-knockdown by co-transfection with Cdh5 mRNA 26
To determine if the vascular defects observed in the siRNA#1-injected 27 embryos were elicited specifically by Cdh5-specific knockdown, we performed rescue 28 experiments using siRNA-resistant Cdh5 mRNA (Fig. 6) Cdh5-siRNA#1-recognizing region of the gene was mutated (Fig. 6A) , was expected to 31 be resistant to Cdh5-siRNA#1-mediated degradation, but sensitive to Cdh5-siRNA#3. 32
To validate this resistance, DF1 cells were co-transfected with Cdh5mutGFP-encoding13 cDNA along with either Cdh5-siRNA#1 or Cdh5-siRNA#3 (Fig. 6A) . Whereas 1 knockdown efficiency (GFP + cells/ mCherry + cells) by Cdh5-siRNA#3 was similar to 2 that in Fig. 3 (0.18 ± 0.11; n=4), Cdh5-siRNA#1 failed to inhibit Cdh5mutGFP (1.11 ± 3 0.10; n=4) (Fig. 6B, C) . Thus, Cdh5mutGFP was resistant against Cdh5-siRNA 4 #1-mediated degradation. 5
Finally, we asked if Cdh5mut mRNA would rescue the in vivo vascular 6 phenotype elicited by Cdh5-siRNA#1. Right dorsal aorta (R-DA) of 16 ss embryo was 7 injected with a 0.8 µl cocktail containing Cdh5-siRNA#1 and Cdh5mut mRNA (12.5% 8 of Lipofectamine 2000, 4 µM of rhodamine-labeled Cdh5-siRNA#1, and 360 ng/µl of 9
Luciferase mRNA or 600 ng/µl of Cdh5mut mRNA), and vascular formation was 10 assessed after 20 hrs at HH16 (Fig. 6D) . When Luciferase mRNA and Cdh5-siRNA#1 11 were co-injected as a control, the vasculature was disrupted in the rhodamine-labeled 12 area as seen in Fig. 4C (Fig. 6E , n=7/7). In contrast, when Cdh5mut mRNA was 13 co-transfected with Cdh5-siRNA#1, overt structures of vitelline artery and yolk sac 14 vasculature with blood circulation were recognized in the rhodamine-labeled area (Fig.  15 6F, n=7/10). Thus, we conclude that the vascular defects seen in 16
Cdh5-siRNA#1-transfected embryos are caused by Cdh5-specific knockdown and not 17 by off-target effects. The results also show that the transfection method described in this 18 study is applicable not only for DNA/plasmid, but also for mRNA products. 
Lipofectamine is useful for infusion-mediated gene transfer 31
We have found that among commercially available reagents commonly used 32 for gene transfection into cultured cells, Lipofectamine 2000 and -3000, the liposomalreagents, give higher efficiency than the non-liposomal reagents, ViaFect, FuGENE HD, 1 and SuperFect (Fig. 1, Table 1 ). This suggests that liposomal components are critical for 2 the infusion-mediated transfection at least into early vasculatures in ovo, and this is 3 consistent with the previous reports in which elaborately prepared liposomal constructs 4 were used for DNA transfection into vasculatures in chicken embryos (Bollerot et al., Although we have not directly compared, the transfection efficiency by Lipofectamine 18 used in the current study appears to be at least comparable with, if not superior to, the 19 efficiency described in the aforementioned previous studies using liposomes prepared 20 by their own (Bollerot et al., 2006; Decastro et al., 2006) . 21
In our hands, whereas the transfection efficiency is comparable between 22
Lipofectamine 2000 and Lipofectamine 3000, the former costs less than the latter. infused cocktail also spreads differently in a stage-dependent manner even when the 1 cocktail is infused into the same site. 2 Differential sites of infusion: When we inject a GFP-Lipofectamine cocktail into the 3 heart after the circulation is established, vasculatures in both right and left halves are 4 equally transfected in addition to the heart (Fig. 2F) . In contrast, when the cocktail is 5 infused into the right dorsal aorta, the vasculature in only the right half of 6 embryo/extraembryo is positive for GFP (Fig. 2I) . 7
Differential time points of infusion: Our infusion-mediated gene transfer in vasculature 8 takes advantage of the blood flow. When a cocktail is infused into the heart at 13 ss 9 when the blood flow is about to start, the transfected area is limited (Fig. 2E) . In 10 contrast, when the cocktail is infused into the heart at 19 ss when the blood flow is more 11 prominent than 13 ss, the infused reagents are more widely spread in the vasculature, 12 resulting in a wide area of transgenesis (Fig. 2G) . early lethality, mainly because of a heart failure (Carmeliet et al., 1999; Gory-Faure et 23 al., 1999; Montero-Balaguer et al., 2009 ). In the current study, we have succeeded, for 24 the first time, in knockdown of the endogenous Cdh5 specifically in the right half 25 vasculature, which results in severe malformation of blood vessels without affecting the 26 heart formation (Fig. 4C) . The rescue experiments using siRNA-resistant mutant Cdh5 27 mRNA indicate that the vascular deficiency elicited by Cdh5-siRNA is not by off-target 28 means (Fig. 6F) . 29
30
In summary, the method described in this study enables efficient gene transfer 31 into early chicken vasculature without affecting heartbeat. Infusion of a cocktail with 32
Lipofectamine, an easy-use reagent, delivers plasmid DNAs, mRNAs, and siRNAs to 33 developing vasculatures. Vascular type-specific transfection can be achieved by 1 adjusting infusion sites and developmental stages of embryos. This method could also 2 be applicable to other experimental animals, facilitating investigations of the formation 3 of peripheral vascular systems, and their roles in tissue and organ formation. 4
5
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